TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6538742

Group type: EXPERIMENTAL
Intervention: Meat (75 g)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Soy protein (equivalent protein content to meat)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cauliflower (65 mg ascorbic acid)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pure ascorbic acid (50 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (6 mg)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Citric acid (1 g)
Number of subjects: 49
Study: 31590286

Group type: EXPERIMENTAL
Intervention: Very-low-calorie ketogenic (VLCK) diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-calorie (LC) diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 79
Study: 30059778

Group type: EXPERIMENTAL
Intervention: Epidural Steroids (ES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 25952591

Group type: EXPERIMENTAL
Intervention: Dynamic standing practice in a modified standing frame
Number of subjects: 28

Group type: COMPARATOR
Intervention: Static standing practice in a conventional standing frame
Number of subjects: 28
Study: 24170109

Group type: EXPERIMENTAL
Intervention: NKB (2.56 or 5.12 nmol/kg/h)
Number of subjects: 34

Group type: COMPARATOR
Intervention: NKB (5.12 nmol/kg/h)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NKB (0.64‐5.12 nmol/kg/h)
Number of subjects: 34
Study: 22556176

Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 210
Study: 20132136

Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) strength training for 12 weeks, three times a week, on a five‐exercise circuit
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group receiving usual care
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Functional progressive resistance exercise (PRE) strength training
Number of subjects: 51
Study: 16956917

Group type: EXPERIMENTAL
Intervention: 16-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 24-week treatment with peginterferon alpha-2a (180 mug/week) and weight-based ribavirin (1000-1200 mg/day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 16-week treatment with RVR
Number of subjects: 150

Group type: COMPARATOR
Intervention: 24-week treatment with RVR
Number of subjects: 150

Group type: COMPARATOR
Intervention: 24-week treatment
Number of subjects: 150
Study: 15542934

Group type: EXPERIMENTAL
Intervention: E3/pravastatin (2 mg E3 and 10 mg pravastatin)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pravastatin (10 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: E3 (2 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 33
Study: 12163293

Group type: EXPERIMENTAL
Intervention: Previously burned skin flaps
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal skin flaps
Number of subjects: 74
Study: 9856958

Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low salt intake (10 mmol/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High salt intake (200 mmol/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low salt intake with ACE inhibition
Number of subjects: 0
Study: 8568984

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (9-month diet-induced)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (9-month program)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (weight-maintenance)
Number of subjects: 170
Study: 2194052

Group type: EXPERIMENTAL
Intervention: 10% lidocaine aqueous gel with 3% glycyrrhetinic acid 3‐0 hemiphthalate disodium (GAHPh)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plain 10% lidocaine aqueous gel without GAHPh
Number of subjects: 24
Study: 393736

Group type: EXPERIMENTAL
Intervention: Mantra meditation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antimeditation control
Number of subjects: 80

Group type: COMPARATOR
Intervention: Progressive-relaxation control
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 80
Study: 31704436

Group type: EXPERIMENTAL
Intervention: Opioid Misuse Prevention Program (OMPP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 76
Study: 30819204

Group type: EXPERIMENTAL
Intervention: Wii Sports Resort intervention group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 27397584

Group type: EXPERIMENTAL
Intervention: F‐SET (False Safety Behavior Elimination Therapy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 28
Study: 26201190

Group type: EXPERIMENTAL
Intervention: SIT group (n = 34) received medication and 3 years of standardized allergen vaccine therapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: ST group (n = 34) received symptomatic therapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SIT group (n = 34)
Number of subjects: 68
Study: 23352749

Group type: EXPERIMENTAL
Intervention: 640 U alum‐adjuvant EV71 vaccine
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: 320 U alum‐adjuvant EV71 vaccine
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1200
Study: 21502544

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 0
Study: 19304671

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1207
Study: 16963472

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 850
Study: 15623060

Group type: EXPERIMENTAL
Intervention: Biolok implants
Number of subjects: 39
Study: 12536700

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medicine
Number of subjects: 0
Study: 9296421

Group type: EXPERIMENTAL
Intervention: Diltiazem (30 mg, per os)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg, per os)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg, per os)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Morphine (10 mg/70 kg, intravenously)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 9
Study: 8413069

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 3755412

Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg, 2 tablets)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 29871567

Group type: EXPERIMENTAL
Intervention: Carpal tunnel decompression with tourniquet
Number of subjects: 73

Group type: COMPARATOR
Intervention: Carpal tunnel decompression without tourniquet
Number of subjects: 73
Study: 27997551

Group type: EXPERIMENTAL
Intervention: Functional constipation among students
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Symptoms of functional constipation
Number of subjects: 1662

Group type: EXPERIMENTAL
Intervention: Association of sex with functional constipation
Number of subjects: 1662
Study: 24945482

Group type: EXPERIMENTAL
Intervention: 4-month preoperative course of aerobic physical training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No aerobic physical training (control group)
Number of subjects: 0
Study: 21535163

Group type: EXPERIMENTAL
Intervention: Hydrogel containing monocaprin and doxycycline (MCD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrogel containing only monocaprin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo hydrogel
Number of subjects: 0
Study: 20227891

Group type: EXPERIMENTAL
Intervention: Intraoperative fentanyl administration
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: C-reactive protein levels
Number of subjects: 113
Study: 18792652

Group type: EXPERIMENTAL
Intervention: Modeling with vicarious reinforcement condition (received 3 personal anecdotes)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control condition (received a fact sheet about problem solving)
Number of subjects: 132
Study: 17214049

Group type: EXPERIMENTAL
Intervention: Ginger (3 capsules of 0.5 g ginger powder each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (3 capsules)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12615014

Group type: EXPERIMENTAL
Intervention: Computer controlled dental anesthetic delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional method of anesthetic delivery
Number of subjects: 0
Study: 11763940

Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 700

Group type: COMPARATOR
Intervention: Comparison brushes (seven leading manual brushes)
Number of subjects: 700
Study: 8853725

Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Alcohol drinking
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Elevated CD8 lymphocyte counts
Number of subjects: 56

Group type: COMPARATOR
Intervention: Zidovudine and aciclovir therapy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Recreational drug use
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral sexual practices
Number of subjects: 56

Group type: COMPARATOR
Intervention: Changes in CD4 and total lymphocyte counts
Number of subjects: 56
Study: 1537726

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 1,000 mg intravenous injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 6
Study: 6594722

Group type: EXPERIMENTAL
Intervention: Endocervical PGE2 gel (400 micrograms)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 gel (400 or 800 micrograms)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (inactive gel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extra-amniotic PGE2 group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endocervical PGE2 group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 30704149

Group type: EXPERIMENTAL
Intervention: Website education cohort (n=19)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paper education cohort (n=19)
Number of subjects: 80
Study: 28625429

Group type: EXPERIMENTAL
Intervention: Automated anesthesia carts
Number of subjects: 1066

Group type: COMPARATOR
Intervention: Conventional manual carts
Number of subjects: 1066
Study: 26501411

Group type: EXPERIMENTAL
Intervention: Treprostinil
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 24102103

Group type: EXPERIMENTAL
Intervention: Humor therapy program with professional performers (ElderClowns) and trained facility staff (LaughterBosses) for a minimum of nine 2-hour sessions over 12 weeks.
Number of subjects: 0
Study: 22433263

Group type: EXPERIMENTAL
Intervention: Motor proficiency assessed using BOTMP-SF
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Motor proficiency divided into quartiles
Number of subjects: 232
Study: 19260050

Group type: EXPERIMENTAL
Intervention: IGIV‐C (10% caprylate/chromatography purified); administered every 3 weeks for up to 24 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo; administered every 3 weeks for up to 24 weeks
Number of subjects: 59
Study: 17318006

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy (PHT)
Number of subjects: 0
Study: 15516697

Group type: EXPERIMENTAL
Intervention: Trandolapril plus verapamil (2 mg per day + 180 mg per day)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg per day)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg per day)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204
Study: 11205181

Group type: EXPERIMENTAL
Intervention: HFA-pMDI through a non-static spacer (Nebuhaler)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CFC-pMDI through a static spacer (Nebuhaler)
Number of subjects: 12
Study: 9771862

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (260 nmol, approximately 4000 IU) daily for 14 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vitamin D2 (260 nmol, approximately 4000 IU) daily for 14 days
Number of subjects: 72
Study: 7921339

Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cinnarizine 50 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg + 10 mg domperidone
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cinnarizine 25 mg + 1 transdermal scopolamine patch
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3378855

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg/die/os
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cimetidine 800 mg/die/os
Number of subjects: 20
Study: 31474438

Group type: EXPERIMENTAL
Intervention: Virtual reality headset wear
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional desktop computer display use
Number of subjects: 20
Study: 28730951

Group type: EXPERIMENTAL
Intervention: NCCT + computed tomography angiography + computed tomography perfusion
Number of subjects: 400

Group type: COMPARATOR
Intervention: NCCT alone
Number of subjects: 400
Study: 26276754

Group type: EXPERIMENTAL
Intervention: Metformin 1,700 mg once daily for 28 days
Number of subjects: 200
Study: 24267729

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 48
Study: 20167357

Group type: EXPERIMENTAL
Intervention: Higher levels of structure in the activity as a whole
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Increasing structure in five-minute intervals within the activity
Number of subjects: 398
Study: 19595060

Group type: EXPERIMENTAL
Intervention: Citrullinated collagen type II (Cit‐CII)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Collagen type II (CII)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anti-Cit‐CII antibody
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anti-CII antibody
Number of subjects: 34
Study: 16234829

Group type: EXPERIMENTAL
Intervention: Drink A (0.1% dairy fat, 2.2% total fat) with a meal
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Drink A without a meal
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Drink B (1.5% dairy fat, 3.3% total fat) with a meal
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Drink B without a meal
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo drink with a meal
Number of subjects: 184
Study: 15659500

Group type: EXPERIMENTAL
Intervention: Intermediate-dose methotrexate (IDM) and high-dose cytarabine (HiDAC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: APO regimen (doxorubicin, vincristine, prednisone, 6-mercaptopurine, and methotrexate)
Number of subjects: 180
Study: 11984212

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (CLT) using pravastatin 10-20 mg per day for 3 years
Number of subjects: 373

Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering therapy (CLT) using pravastatin
Number of subjects: 373
Study: 9868971

Group type: EXPERIMENTAL
Intervention: Insulin + Metformin (2.55 g daily in three divided doses, n = 24)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Moderate insulin dose increase (20% of baseline, n = 23)
Number of subjects: 47
Study: 7613532

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 400 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Megestrol acetate 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2694713

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Comfeel Ulcus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wet saline gauze dressing
Number of subjects: 0
Study: 822782

Group type: EXPERIMENTAL
Intervention: 30% aluminum chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbol-fuchsin solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminum chlorohydrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminum acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aluminum chloride
Number of subjects: 0
Study: 31981833

Group type: EXPERIMENTAL
Intervention: Botulinum toxin with local anaesthetic (BTX)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local anaesthetic (LA) alone
Number of subjects: 80
Study: 31729052

Group type: EXPERIMENTAL
Intervention: Nonablative fractional laser therapy (FLT) followed by photodynamic therapy (PDT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combined FLT-PDT treatment
Number of subjects: 11
Study: 31340588

Group type: EXPERIMENTAL
Intervention: Exercise intervention (12-week community-based randomized controlled trial)
Number of subjects: 45
Study: 27998950

Group type: EXPERIMENTAL
Intervention: Listerine Cool Mint
Number of subjects: 196

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 196
Study: 26258448

Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: General self-efficacy
Number of subjects: 337
Study: 23391030

Group type: EXPERIMENTAL
Intervention: 15% H2O2 and nitrogenous-titanium-dioxide with light activation (Group A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 35% H2O2 with light activation (Group B)
Number of subjects: 87

Group type: COMPARATOR
Intervention: 35% H2O2 without light activation (Group C)
Number of subjects: 87
Study: 21703382

Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of fruit (0.9 servings/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of cookies
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of potato chips
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fathers' dietary intake of vegetables (2.2 servings/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Children's intake of ice cream, chocolate, or french fries
Number of subjects: 50
Study: 19139433

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) 10 mg/kg every 14 days and Erlotinib (E) 150 mg orally daily, continuously, for 28-day cycles
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) and Erlotinib (E)
Number of subjects: 40
Study: 17110262

Group type: EXPERIMENTAL
Intervention: Heavy force (225 g)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Light force (25 g)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control force (0 g)
Number of subjects: 54
Study: 14975482

Group type: EXPERIMENTAL
Intervention: Acute total sleep deprivation (88 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-term partial sleep deprivation (4.2 hours of sleep for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (8.2 hours of sleep for 10 days)
Number of subjects: 20
Study: 11312068

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (20 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (whey protein)
Number of subjects: 0
Study: 9143867

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg every 6 h for 10 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg every 12 h for 7 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of zileuton and terfenadine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7945979

Group type: EXPERIMENTAL
Intervention: Autonomic responses during performance of an anticipation task
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Six task modalities
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Autonomic variables
Number of subjects: 11
Study: 3129596

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support (PNS) with 30 kcal/kg/day and 200 mg/kg/day of nitrogen for at least 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no preoperative nutritional support)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support (PNS) in malnourished patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (malnourished patients without PNS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support (PNS) in malnourished patients undergoing gastrectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (malnourished patients undergoing gastrectomy without PNS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Preoperative nutritional support (PNS)
Number of subjects: 100
Study: 29693279

Group type: EXPERIMENTAL
Intervention: Partially microgrooved healing abutments (n=15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Machined healing abutments (n=13)
Number of subjects: 28
Study: 28376151

Group type: EXPERIMENTAL
Intervention: Systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection
Number of subjects: 119

Group type: COMPARATOR
Intervention: Systemic treatment alone
Number of subjects: 119
Study: 26762075

Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring in patients with arterial hypertension during acute gastrointestinal bleeding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Holter monitoring in patients with arterial hypertension during acute gastrointestinal bleeding
Number of subjects: 45
Study: 23606168

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190